Evidence map›Paper›PMID 34625573›Full record

ArticleScientific reports2021

Simultaneous analysis of urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, N'-nitrosonornicotine, and cotinine by liquid chromatography-tandem mass-spectrometry.

Sampada S Nikam, Murari Gurjar, Hitesh Singhavi, Anand Patil, Arjun Singh, Peter Villalta, Pankaj Chaturvedi, Samir S Khariwala, Vikram Gota, Irina Stepanov

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Sampada S NikamDepartment of Clinical Pharmacology, Advanced Centre for Training, Research and Education in Cancer (ACTREC), Mumbai, India.
Murari GurjarDepartment of Clinical Pharmacology, Advanced Centre for Training, Research and Education in Cancer (ACTREC), Mumbai, India.
Hitesh SinghaviTata Memorial Centre, Mumbai, India.
Anand PatilDepartment of Clinical Pharmacology, Advanced Centre for Training, Research and Education in Cancer (ACTREC), Mumbai, India.
Arjun SinghTata Memorial Centre, Mumbai, India.
Peter VillaltaMasonic Cancer Center, University of Minnesota, 2231 6th Street SE, Minneapolis, MN, 55455, USA.
Pankaj ChaturvediTata Memorial Centre, Mumbai, India.
Samir S KhariwalaDepartment of Otolaryngology, Head and Neck Surgery, Medical School, University of Minnesota, Minneapolis, USA.
Vikram GotaDepartment of Clinical Pharmacology, Advanced Centre for Training, Research and Education in Cancer (ACTREC), Mumbai, India. vgota@actrec.gov.in.
Irina StepanovMasonic Cancer Center, University of Minnesota, 2231 6th Street SE, Minneapolis, MN, 55455, USA. stepa011@umn.edu.
Tata Memorial Hospital · INAdvanced Centre for Treatment, Research and Education in Cancer · INHomi Bhabha National Institute · INUniversity of Minnesota · USUniversity of Minnesota Medical Center · US

Funding

Nornicotine in smokeless tobacco as a precursor for carcinogen exposureR01CA180880 · NCI · UNIVERSITY OF MINNESOTA · PI STEPANOV, IRINA · 2014 to 2018
$2.4M
Mass Spectrometric Analytical Collaborations with Members of the Masonic Cancer Center of the University of MinnesotaR50CA211256 · NCI · UNIVERSITY OF MINNESOTA · PI Peter William Villalta · 2016 to 2026
$2.1M
Analytical capacity building for the study of tobacco carcinogen exposures in IndiaR01TW010651 · FIC · UNIVERSITY OF MINNESOTA · PI CHATURVEDI, PANKAJ, KHARIWALA, SAMIR S · 2017 to 2021
$1.4M
FIC NIH HHS R01 TW010651FIC NIH HHS R01-TW010651NCI NIH HHS R01 CA180880NCI NIH HHS R01-CA180880NCI NIH HHS R50 CA211256
6 · The paper itself

Abstract

Biomarkers of exposure to harmful tobacco constituents are key tools for identifying individuals at risk and developing interventions and tobacco control measures. However, tobacco biomarker studies are scarce in many parts of the world with high prevalence of tobacco use. Our goal was to establish a robust method for simultaneous analysis of urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), N'-nitrosonornicotine (NNN), and cotinine at the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) in Mumbai, India. These biomarkers are validated measures of exposure to the carcinogenic tobacco nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and NNN and the addictive alkaloid nicotine, respectively. The established method is characterized by excellent accuracy, linearity, and precision, and was successfully applied to the analysis of 15 smokeless tobacco (SLT) users and 15 non-users of tobacco recruited in Mumbai. This is the first report of establishment of such procedure in a laboratory in India, which offers the first in-country capacity for research on tobacco carcinogenesis in Indian SLT users.

Indexed as

BiomarkersCarcinogensChromatography, LiquidCotinineHumansNitrosaminesTandem Mass SpectrometryTobacco ProductsTobacco Use4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-olBiomarkersCarcinogensCotinineNitrosaminesN'-nitrosonornicotine

Identifiers

PMID34625573
PMCPMC8501032
OpenAlexW3202086172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.